 Shareholder rights law firm Robbins LLP reminds investors that purchasers of Immunomedics, Inc. NASDAQ: IMMU filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between April 20, 2016 and June 2, 2016. Immunomedics, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer. The company is developing its antibody-drug conjugate IMMU-12. 